Complete last patient visit for Mino-Lok trial
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Last Pat. Visit est. Q2’21”
What we found
Evidence strength A What the grades mean
The company did not report completing the last patient visit for the Mino-Lok trial by the Q2 2021 deadline; subsequent filings indicate the trial was still ongoing.
-
A Citius Pharmaceuticals, Inc. 8-K filed 2021-07-07
“Phase 3 multicenter trial is currently enrolling patients” ✓ confirmed on the page
-
A Citius Pharmaceuticals, Inc. 8-K filed 2021-08-12
“We remain encouraged by the positive recommendation of the independent DMC to continue the Mino-Lok® Phase 3 pivotal superiority trial as planned” ✓ confirmed on the page
Market reaction: the shares moved +1.2% against the S&P 500 over the three sessions around the disclosure (6 Jul 2021 to 9 Jul 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Mino-Lok trial last patient visit
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Citius Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CTXR-021664 · Corrections policy